Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease

Clinics

Volumn 66, Issue 10, 2011, Pages 1677-1680

  Ma, Shao Gang ^a   Wei, Chun Ling ^a   Hong, Bing ^a   Yu, Wei Nan ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Diabetes mellitus; Ischemia modified albumin; Peripheral arterial disease; Risk factors

Indexed keywords

BIOLOGICAL MARKER; ISCHEMIA MODIFIED ALBUMIN; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

AGE; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD; BLOOD PRESSURE; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGY;

AGE FACTORS; AGED; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; SERUM ALBUMIN;

EID: 80054774237     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011001000003     Document Type: Article

References (25)

1. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005;12:443-52.
2. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-53, doi: 10.1001/jama.295.5.547.
3. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472-9.
4. Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med. 2001;6(3 Suppl):3-7, doi: 10.1177/1358836X0100600i102.
5. Li J, Luo Y, Xu Y, Yang J, Zheng L, Hasimu B, et al. Risk factors of peripheral arterial disease and relationship between low ankle-brachial index and mortality from all-cause and cardiovascular disease in Chinese patients with type 2 diabetes. Circ J. 2007;71:377-81, doi: 10.1253/circj.71.377.
6. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis. 2007;190:84-9, doi: 10.1016/j.atherosclerosis.2006.02.017.
7. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-5, doi: 10.1001/jama.285.19.2481.
8. Zanati SG, Mouraria GG, Matsubara LS, Giannini M, Matsubara BB. Profile of cardiovascular risk factors and mortality in patients with symptomatic peripheral arterial disease. Clinics. 2009;64:323-6, doi: 10.1590/S1807-59322009000400010
9. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol. 2010;55:2017-23, doi: 10.1016/j.jacc.2009.08.090.
10. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008;148:85-93.
11. da Silva SH, Hausen Bdos S, da Silva DB, Becker AM, de Campos MM, Duarte MM, et al. Characteristics of a nickel-albumin binding assay for assessment of myocardial ischaemia. Biomarkers. 2010;15:353-7, doi: 10.3109/13547501003763369.
12. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G, et al. Ischemia-modified albumin levels predict longterm outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J. 2010;159:570-6, doi: 10.1016/j.ahj.2009.12.026.
13. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311-5, doi: 10.1016/S0736-4679(00)00255-9.
14. Fagan GJ, Wayment H, Morris DL, Crosby PA. The albumin cobalt binding test: analytical performance of a new automated chemistry assay for the detection of ischemia modified albumin (IMA). J Clin Ligand Assay. 2002;25:178-87.
15. Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P. Analytical performance of the albumin cobalt binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med. 2004;42:455-61, doi: 10.1515/CCLM.2004.079.
16. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med. 2007;24:333-43, doi: 10.1111/j.1464-5491.2007.02106.x
17. Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Hacihasanoglu AB, et al. Anovel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009;36:425-32, doi: 10.1007/s12020-009-9236-5.
18. Bragadeesh T, Sari I, Pascotto M, Micari A, Kaul S, Lindner JR. Detection of peripheral vascular stenosis by assessing skeletal muscle flow reserve. J Am Coll Cardiol. 2005;45:780-5, doi: 10.1016/j.jacc.2004.11.045.
19. Wu WC, Mohler E 3rd, Ratcliffe SJ, Wehrli FW, Detre JA, Floyd TF. Skeletal muscle microvascular flow in progressive peripheral artery disease: assessment with continuous arterial spin-labeling perfusion magnetic resonance imaging. J Am Coll Cardiol. 2009;53:2372-7, doi: 10.1016/j.jacc.2009.03.033.
20. Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43:450-4, doi: 10.1016/j.clinbiochem.2009.11.018
21. Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56:187-90.
22. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-Preliminary report. Dis Markers. 2008;24:311-7.
23. Aronow WS, Ahn C, Weiss MB, Babu S. Relation of increased hemoglobin A(1c) levels to severity of peripheral arterial disease in patients with diabetes mellitus. Am J Cardiol. 2007;99:1468-9, doi: 10.1016/j.amjcard.2006.12.085.
24. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-57, doi: 10.1001/jama.274.13.1049
25. Darius H, Pittrow D, Haberl R, Trampisch HJ, Schuster A, Lange S, et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross- sectional study of 6880 primary care patients. Eur J Clin Invest. 2003;33:751-7, doi: 10.1046/j.1365-2362.2003.01196.x